Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
| 35.66 Delayed Data As of May 22 |  -0.18 / -0.50%Today’s Change | 19.51 Today|||52-Week Range 73.72 | -43.78% Year-to-Date |
Latest ARWR News | Press Releases
| Is Arrowhead Pharmaceuticals a Buy? May 24 / MotleyFool.com - Paid Partner Content | Will Arrowhead Pharmaceuticals Be a Biotech Winner? May 19 / MotleyFool.com - Paid Partner Content |
| Is Alnylam Pharmaceuticals a Buy? May 21 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 35.84 |
| Today’s open | 35.79 |
| Day’s range | 34.87 - 35.84 |
| Volume | 57,948 |
| Average volume (3 months) | 1,588,921 |
| Market cap | $3.6B |
Data as of 4:00pm ET, 05/22/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -172.86% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +945.67% |
| P/E ratio | 396.2 |
| Price/Sales | 16.46 |
| Price/Book | 13.96 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BPMCBlueprint Medicines ... | +0.58 | +0.90% |
| MNTAMomenta Pharmaceutic... | +0.54 | +1.68% |
| HALOHalozyme Therapeutic... | +0.15 | +0.61% |
| DCPHDeciphera Pharmaceut... | -0.44 | -0.74% |
Data as of 4:00pm ET, 05/22/2020
Financials
| Next reporting date | August 11, 2020 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $168.8M |
| Annual profit (last year) | $68.0M |
| Net profit margin | 40.27% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Pasadena, California |
Forecasts
